Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026

ConferenceHLP003Neutral

AI Analysis

Summary

Helus Pharma presented new analyses on HLP003, an adjunctive treatment candidate for major depressive disorder, at Psych Congress 2026, including data from the Phase 3 PARADIGM program.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Poster presentations on HLP003 clinical profile and Phase 3 PARADIGM program data

Importance:4/10

Sentiment:

0.00

Phase 3Major Depressive DisorderAdjunctive TreatmentConference Presentation

Read the original article

Published by GlobeNewswire Clinical Studies on September 21, 2026 11:30 AM

Read Original